950160 — Kolon TissueGene Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapMomentum Trap

Annual cashflow statement for Kolon TissueGene, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-41.4	-8.62	-13.2	-24.8	-135
Depreciation
Amortisation
Non-Cash Items	0.65	-3.45	-2.13	8.77	120
Unusual Items
Other Non-Cash Items
Changes in Working Capital	4.42	-9.94	-4.22	0.42	-2.24
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-35	-20.7	-18.5	-15	-16.9
Capital Expenditures	-5.36	-18.8	-35.4	-56.6	-82.6
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	34.6	-12.2	13.1	0.005	-9.97
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	29.2	-31	-22.2	-56.6	-92.6
Financing Cash Flow Items	—	23.7	—	—	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	21.5	51.8	29.2	50.9	156
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	15.7	0.056	-11.5	-20.7	46.7